Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
Holding ATHA?
Track your performance easily
ATHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $4.30
Previous Close$0.46
Volume731.53K
Average Volume (3M)680.22K
Market Cap
$17.98M
Enterprise Value-$72.56M
Total Cash (Recent Filing)$91.77M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 07, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding38,439,375
10 Day Avg. Volume1,540,532
30 Day Avg. Volume680,224
Standard Deviation0.25
R-Squared0.31
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
$1.44Price Target Upside207.89% Upside
Rating ConsensusHold
Number of Analyst Covering6
Athira Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsResults from the Phase 2/3 LIFT-AD trial evaluating fosgonimeton for the treatment of mild-to-moderate Alzheimer’s disease are on track to read out.
Drug DevelopmentThe FDA seems supportive in fostering drug development for rare neuro diseases, such as granting expedited pathways.
RestructuringATHA announced new restructuring efforts leading to significant annualized cost savings.
Bears Say
Clinical TrialsThe Phase 2/3 LIFT-AD trial did not meet its primary or key secondary endpoints.
Cost-Cutting MeasuresThe company announced cost-cutting measures, including a workforce reduction of 70%, which extends projected cash runway through 1Q26.
Investor SentimentInvestor sentiment on ATHA is bearish, given that HGF/MET is poorly understood, remains largely unproven, and is outside the box relative to more mainstream thinking.
---
Ownership Overview
31.58% Insiders
11.61% Mutual Funds
51.43% Other Institutional Investors
5.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $0.46 and its highest was $4.30 in the past 12 months.
What is Athira Pharma’s market cap?
Currently, no data Available
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on Aug 01, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.037.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Undervalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -$0.7.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 38,439,377 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went down -1.231%.
Which hedge fund is a major shareholder of Athira Pharma?
Among the largest hedge funds holding Athira Pharma’s share is Perceptive Advisors LLC. It holds Athira Pharma’s shares valued at 14M.
---
Athira Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.44 (207.89% Upside)
$1.44 (207.89% Upside)
Hedge Fund Trend
Increased
By 27.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $92.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.7%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.25%
12-Months-Change
Fundamentals
Return on Equity
-84.57%
Trailing 12-Months
Asset Growth
-46.53%
Trailing 12-Months
Company Description
Athira Pharma
Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.
---
ATHA Stock 12 Month Forecast
Average Price Target
$1.44
▲(207.89% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Cabaletta Bio
―
Corbus Pharmaceuticals
―
Kintara Therapeutics
―
---